Lighthouse Pharma leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders. The team has a decade of data informing their strategy, including patient responder analyses, rigorous dose modeling, and clinical execution.
Company update from CEO Casey Lynch 2.6.2024
Leadership Team
UPDATE
〰️
11/16/23
〰️
UPDATE 〰️ 11/16/23 〰️
Lighthouse announces FDA approval to proceed with Phase 2 SPRING Trial of LHP588
The “Study May Proceed” notification from the FDA was based on review of the comprehensive IND package including safety, chronic toxicology, manufacturing, Phase 1 human data, and the planned Phase 2 SPRING (Stopping PRogression of P. gINGivalis-positive Alzheimer’s disease) trial protocol.
“LHP588 is a next-generation gingipain inhibitor that has been optimized for selectivity and metabolism, demonstrating an excellent safety profile in both human and toxicology studies. With FDA clearance in hand, we look forward to working with our clinical advisors and investors to move this important clinical study forward.”
The planned Phase 2 SPRING clinical trial is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of once-a-day dosing of LHP588 for the treatment of P. gingivalis-positive mild to moderate Alzheimer’s disease. 300 patients will be enrolled in the trial and randomized into three arms (placebo, 25 and 50 mg) for 48 weeks of treatment. Patients must have mild to moderate Alzheimer’s disease and evidence of P. gingivalis infection, based on a saliva test.
Previous Videos
By 2050, the number of people aged 65 and older with Alzheimer's and dementia is projected to reach 12.7 million.
Lighthouse Pharmaceuticals is backed by Portfolia’s Active Aging & Longevity Fund II. The Fund focuses on answering the question: how do we live healthy and enriching lives into old age, and what choices do people of all ages make today to ensure that they live long, healthy and enriching lives. Lighthouse Pharmaceuticals is changing the way we treat disease, and their approach leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders.
Join us to learn more about these treatments, and how you can back companies revolutionizing the active aging & longevity space for returns and impact